{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-026895","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2022-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.937384+00:00","generated_at":"2026-06-23T01:44:33.971868+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Prime Medicine amends charter and bylaws upon IPO closing","bullets":["Third amended charter authorizes 775M shares common and 10M shares undesignated preferred.","Bylaws eliminate stockholder written consent and restrict special meetings.","Advance notice procedure adopted for stockholder proposals and director nominations.","Changes became effective immediately prior to IPO closing on October 19, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-026895","json":"https://secwatch.observer/filing/0001628280-22-026895.json","markdown":"https://secwatch.observer/filing/0001628280-22-026895.md","text":"https://secwatch.observer/filing/0001628280-22-026895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828022026895/0001628280-22-026895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828022026895/prime-closing8xk102222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:44:33.971868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}